Abstract 4556: Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma

MLA

Hao Cai, et al. “Abstract 4556: Preclinical Pharmacology and Safety of RO7297089, a Novel Anti-BCMA/CD16a Bispecific Antibody for the Treatment of Multiple Myeloma.” Cancer Research, vol. 80, Aug. 2020, p. 4556. EBSCOhost, https://doi.org/10.1158/1538-7445.am2020-4556.

APA

Hao Cai, Stefan Knackmuss, Steve R. Leong, Luna Liu, Nicholas Corr, Bing Zheng, Shelly Zhong, Lanlan Yu, Thorsten Ross, Uwe Reusch, Christoph Spiess, Michael Dillon, Sivan Cohen, Adeyemi O Adedeji, Satoko Kakiuchi-Kiyota, Susanne Wingert, Andrew Polson, Robert Hendricks, Melissa Schutten, … Ayse M. Ovacik. (2020). Abstract 4556: Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma. Cancer Research, 80, 4556. https://doi.org/10.1158/1538-7445.am2020-4556

Chicago

Hao Cai, Stefan Knackmuss, Steve R. Leong, Luna Liu, Nicholas Corr, Bing Zheng, Shelly Zhong, et al. 2020. “Abstract 4556: Preclinical Pharmacology and Safety of RO7297089, a Novel Anti-BCMA/CD16a Bispecific Antibody for the Treatment of Multiple Myeloma.” Cancer Research 80 (August): 4556. doi:10.1158/1538-7445.am2020-4556.